orkambi reimburs agreement secur
franc estimate increment pt elig
vertex commerci execut continu orkambi reimburs agreement
franc impact recent agreement england orkambi symkevi
see nh england deal encourag vertex progress franc hint
recent healthcar confer takeaway franc agre reimburs orkambi
homozyg patient age two year older expand previou name patient
access scheme patient age year older importantli vertex fulli
recogn revenu orkambi sale franc expect revenu reflect come
agreement must publish offici french regist
compani believ happen estim suggest approxim
homozyg patient franc age older increment age
ahead vertex estim believ overli conserv assum net price
approxim per patient per year see increment revenu
franc fulli recogn recognit revenu prior period impact
non-gaap number fulli model french orkambi revenu
patient year older increas tp total valu
franc opportun reiter outperform
symkevi trikafta exclud agreement franc unlik commit
portfolio deal would like see reimburs symkevi trikafta if/when
approv ema franc see us trikafta approv think good first step
vertex speak compani franc typic take portfolio approach
reimburs henc symkevi trikafta includ expect pressur
patient group continu get product reimburs symkevi ahead trikafta
trikafta yet approv estim french residu function popul
age het-min addit look ahead could see upsid vertex
could secur reimburs symkevi trikafta franc valu
model changes/ risk increas ep base today
agreement risk clinic development commerci regulatori
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
vertex engag develop commerci therapeut
rare diseas includ main franchis cystic fibrosi
scenario assum dcf valu share
cut sg respect assum
posit proof-of-concept data next gener cf asset
also assum posit data updat pipelin asset vx-
gene-edit system
grey sky scenario model less credit trikafta due
lower expect commerci perform regulatori delay
 close
expect formal reimburs begin increment
current valuat new agreement franc add increment
po valuat given previous includ risk-adjust sale
orkambi franc model po overal valu french opportun
vertex gain addit reimburs symkevi trikafta assum
approv eu estim addit upsid increment
opportun current model
believ vertex receiv reimburs start conserv assum
take remaind orkambi formal ad french registri
price estim annual net cost per patient base discount
german kalydeco premium price estim uk actual
cost could publicli avail agreement publish french offici
model chang increas estim franc given today new reimburs
agreement increas probabl success po franc orkambi sale
assum orkambi reimburs start previous
result chang forecast revenu
non-gaap ep made chang estim
valuat target price deriv dcf analysi use wacc
termin growth forecast cash flow account known
expect product launch patent expir competit threat current
commerci portfolio pipelin beyond forecast period appli termin
growth rate termin cash flow believ vertex continu invest
 bd success replac revenu faster rate eros
vertex residu cf opportun ex cf opportun ex revenu loss incom cs dilut cs charl martineau univers toronto novemb
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv vertex investig product
commerci sale
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
